Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 143 Publications

21 Customer Reviews

  • Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NUfyUoxyS3m2b4TvfIlkKEG|c3H5 NVixTWpkPTBizszN NGDabVg1QCCq MmTlSG1UVw>? MYHLbYxteyClZXzsd{BjgSCvb4LlJJRp[W5iOUml MkTkNVA1QTl4NEO=
OVCA 429 MWXGeY5kfGmxbjDBd5NigQ>? NVfVUWJ5OzByIH7N NV:0b3JyPDhiaB?= M3y4WmROW09? NF7sdldFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM> MUexNFk6QTd4Nh?=
RPMI8226 MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOxNFAhdk1? NUPJfmtlPDhiaB?= MoTiSG1UVw>? NGXrc3JKSzVyPUOwJI5O NXvSSWJZOTF|ME[0PFk>
Dox40 NEPnS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:xNFAhdk1? NEjhRWM1QCCq MlvDSG1UVw>? MYTJR|UxRTRyIH7N NHfub4cyOTNyNkS4PS=>
MR20 M{HYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzRNVAxKG6P M1\sc|Q5KGh? NEPodVhFVVOR MXTJR|UxRTJyIH7N MWixNVMxPjR6OR?=
LR5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnaPGMyODBibl2= MmfsOFghcA>? NXvhZXo6TE2VTx?= M3;LTmlEPTB;MkCgcm0> MUWxNVMxPjR6OR?=
U266 NWnYWnk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm3NVAxKG6P MVG0PEBp MmjYSG1UVw>? NITYNnhKSzVyPUOgcm0> NHzYOIQyOTNyNkS4PS=>
IM-9 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXwdopKOTByIH7N MmGwOFghcA>? MlrlSG1UVw>? MYHJR|UxRTZibl2= NWTXNZlCOTF|ME[0PFk>
Hs Sultan MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjGUVZ5OTByIH7N MkX3OFghcA>? MkTJSG1UVw>? NHPFcFBKSzVyPUKwJI5O MXOxNVMxPjR6OR?=
PAM-LY2 NVrrO|NxTnWwY4Tpc44hSXO|YYm= Mmq2NVAxKG6P NFnNNVUyOiCq MljMSG1UVw>? NI\GNWhKdmirYnn0d{BPTi4QulKgZYN1cX[jdHnvci=> NX60XnNJOTF|NUC5NVM>
PAM 212 M32yW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\FenhFOTByIH7N NEXkXWY4OiCq NHe0SZpFVVOR MoXXTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NWLG[YU4OTF|NUC5NVM>
PAM-LY2 M4TDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjPWGQyODBibl2= M3n5cFczKGh? MUHEUXNQ NFLlc4tKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= Mme5NVE{PTB7MUO=
B4B8 MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G4clExOCCwTR?= NXm2Z3VmPzJiaB?= NEfzcoJFVVOR MmXyTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NW\OW4VZOTF|NUC5NVM>
B7E3 M1jh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqxNFAhdk1? NV\zRVg4PzJiaB?= NF;XcphFVVOR MnjQTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MV6xNVM2ODlzMx?=
UM-SCC-9 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHG4bpQyODBibl2= NHWzWIE4OiCq NF;PWolFVVOR M{DxUGlvcGmkaYTzJINmdGxidnnhZoltcXS7 MUCxNVM2ODlzMx?=
UM-SCC-11B NF;B[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfFe2dnOTByIH7N NFr4eYg4OiCq NHzY[mNFVVOR NUiye4s{UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NUTlVpJ4OTF|NUC5NVM>
H460 MmW3SpVv[3Srb36gRZN{[Xl? NVf6WnJLOTBizszN M4X4VlI1KGh? MnOwSG1UVw>? MX3JcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 M1\PTlEzPDl{MUG3
U266 NIrHVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTWfm5jPTByIH7nM41t NYnVSnljPDhiaB?= MkH4SG1UVw>? MXHJcohq[mm2czDj[YxtKGe{b4f0bC=> NFS3XWYyOjZ|MU[xPS=>
ARH77 MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHJV3JzPTByIH7nM41t Ml\SOFghcA>? MV7EUXNQ M2f6dWlvcGmkaYTzJINmdGxiZ4Lve5Rp NYjZUJYyOTJ4M{G2NVk>
WAD-1 NYjRPZI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfsbVI2ODBibnevcYw> NVjTU2FWPDhiaB?= Mo\PSG1UVw>? NIrZToZKdmirYnn0d{Bk\WyuIHfyc5d1cA>? M3rKVFEzPjNzNkG5
U266/LR7 NULmVFQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u1NFUxOCCwZz;tcC=> NHfyN4E1QCCq NWHPc3RtTE2VTx?= NUHFZpc1UW6qaXLpeJMh[2WubDDndo94fGh? M4TMeVEzPjNzNkG5
U266/dox4 M4HDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TXPFUxOCCwZz;tcC=> NULVNHd{PDhiaB?= M2LCXGROW09? MoDmTY5pcWKrdIOgZ4VtdCCpcn;3eIg> M4naNlEzPjNzNkG5
RPMI8226/LR5 M{m5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvJZVF[PTByIH7nM41t Ml;4OFghcA>? M2rxUWROW09? Mn;5TY5pcWKrdIOgZ4VtdCCpcn;3eIg> MkTuNVI3OzF4MUm=
H460 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP6RocyOCEQvF2= MXK3NkBp M{DGZWROW09? M4jpc2lEPTB;MUCwJI5O NGH4SmYyOjZ|MU[yNC=>
H358 NGTvUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[xNEDPxE1? Mn3CO|IhcA>? NID3colFVVOR MlLKTWM2OD15MDDuUS=> MXuxNlY{OTZ{MB?=
H322 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWw[4IyOCEQvF2= NVKyW41CPzJiaB?= M1HqW2ROW09? MWPJR|UxRTZ{MDDuUS=> NXPYemI5OTJ4M{G2NlA>
H460 MUTGeY5kfGmxbjDBd5NigQ>? MXOxNFAhdk1? MV[yOEBp MVfEUXNQ M2LuV2lv\HWlZYOgS|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO|ZX3icJku\Gm|YYPz[Y1jdHl? MoDoNVI3OzF4MkC=
LNCap-Pro5 Mm\1SpVv[3Srb36gRZN{[Xl? NXHhTIJOOSEQvF2= NYnmd3B2PCCq MlL5SG1UVw>? MVXTeIFjcWyrenXzJJA2Ow>? NXjQT2o4OTR4MUK1N|I>
T29 MW\BdI9xfG:|aYOgRZN{[Xl? MVW1NEBvVQ>? MlLTOFghcCB? M1L2fmROW09? NUPkT5g2UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MlPiNVY4PzhzN{m=
T29Kt1 MVLBdI9xfG:|aYOgRZN{[Xl? MnvWOVAhdk1? MVG0PEBpKA>? MmmwSG1UVw>? NHfic49KdmS3Y3XzJINmdGxiYYDvdJRwe2m| M13DVlE3Pzd6MUe5
HCT116 MXnBdI9xfG:|aYOgRZN{[Xl? MXK1NEBvVQ>? NHP4eIk1QCCqIB?= MULEUXNQ NXH5SnRuUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M4PWVVE3Pzd6MUe5
HKe-3 NYW4OpdWSXCxcITvd4l{KEG|c3H5 MXy1NEBvVQ>? M4\oc|Q5KGhi NHizNFhFVVOR NHrkUoNKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NFTIOFAyPjd5OEG3PS=>
NB-1691 NWK3[po3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXSxJO69VQ>? NH6wN2U4OiCq M17BS2lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB3JR?= M1P1O|E4Pjh7Nki0
CHLA-255 NVLBfGtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV73Xoo2OSEQvF2= Ml62O|IhcA>? NGT5OlVKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMjW= NX;ldW9JOTd4OEm2PFQ>
SK-N-AS NILKTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXixJO69VQ>? NEjlelA4OiCq M{\jW2lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyBzMDW= NF3NNmEyPzZ6OU[4OC=>
NB-1691 MknMSpVv[3Srb36gRZN{[Xl? NFPzO2wyOCCwTR?= M3i2[|I1KGh? MoPqV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KGOnbHzzJIlvKHSqZTDHNE9IOSCyaHHz[S=> M1KzRVE4Pjh7Nki0
CHLA-255 MYHGeY5kfGmxbjDBd5NigQ>? M3T6[FExKG6P M4rYUFI1KGh? Mn3TUY9l\XO2bImgdoVlfWOnczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2V? Mke5NVc3QDl4OES=
RPMI 8226 NXzaVlVPTnWwY4Tpc44hSXO|YYm= MkDpNlAhdk1? MWG4JIg> M17lW3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MV2xPVQ{PjB3MB?=
MM.1S Mln4SpVv[3Srb36gRZN{[Xl? NX;5TmdIOjBibl2= NIPBVFY5KGh? NVrXcHJsW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? Mke4NVk1OzZyNUC=
U266 Moi0SpVv[3Srb36gRZN{[Xl? NYPTWVNSOjBibl2= NIHUZoc5KGh? M2nBcHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NEDufYwyQTR|NkC1NC=>
OPM1 NXuxe2lZTnWwY4Tpc44hSXO|YYm= M2nUVFIxKG6P MYO4JIg> MWXTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NHnHcoMyQTR|NkC1NC=>
INA6 M3TUbWZ2dmO2aX;uJGF{e2G7 NEnxZYQzOCCwTR?= MYO4JIg> MnflV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MlvHNVk1OzZyNUC=
OPM2 MYnGeY5kfGmxbjDBd5NigQ>? M3;NUlIxKG6P NGXlSVg5KGh? NIHkcm5UcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NXXwR|J[OTl2M{[wOVA>
RPMI 8226 NXTRSIFFTnWwY4Tpc44hSXO|YYm= NX;3[HM4OjBibl2= NFvUbpQ5KGh? M3G5VWlv\HWlZYOgSG5CKHO7boTo[ZNqew>? NYTCXHFOOTl2M{[wOVA>
BaF/3 NWOxSlZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjSUHFjOTByIH7N Moj3OFghcA>? Mkm0TWM2OD14LkKgcm0> M37RTVIxOzB3Nkmy
BaF/3-p210 NVrhVplHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGxNFAhdk1? NH7jNIw1QCCq Mlj2TWM2OD12Lkegcm0> NFTLWIczODNyNU[5Ni=>
TCC-S MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFntZ5IyODBibl2= NGjLV3k1QCCq M2nWc2lEPTB;Mj64JI5O M4X0O|IxOzB3Nkmy
BaF/3 M1TmeWZ2dmO2aX;uJGF{e2G7 MlHmOkBvVQ>? NUHaTVM5PDhiaB?= M1yzWGlv\HWlZYOgZUBoemWjdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> MXeyNFMxPTZ7Mh?=
BaF/3-p210 NEHPRXdHfW6ldHnvckBCe3OjeR?= NEW3N3g3KG6P MnnPOFghcA>? Mn;6TY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> NUfvbZlGOjB|MEW2PVI>
BaF/3-p210 MYPGeY5kfGmxbjDBd5NigQ>? MkTQOkBvVQ>? NFrY[mQzPCCq MWHS[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gZY5lKHSqZTDhZ5Rqfmm2eTDv[kBT[g>? MW[yNFMxPTZ7Mh?=
Raji MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDBNUDPxE1? MorTNlQhcA>? NVnqUVlHWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NFnQUWszOTF5MEm4PC=>
LCL-1 NYPHR49TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPFWIsyKM7:TR?= NXSwSZdHOjRiaB?= MXLS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NXexbpU5OjFzN{C5PFg>
LCL-2 NVm0PVhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6xJO69VQ>? NVO1VXFLOjRiaB?= NVvUeWgxWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NWTMNYZOOjFzN{C5PFg>
BJAB NUjpZnExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvEZ2VZOSEQvF2= NGLvW|IzPCCq M1rUXnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MnW3NlEyPzB7OEi=
SNT-13 NWjZSod3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6zfXQyKM7:TR?= MXSyOEBp M3HmVHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MUWyNVE4ODl6OB?=
SNT-16 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknFNUDPxE1? Ml75NlQhcA>? MoTTVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M2DLS|IyOTdyOUi4
Jurkat NGL2UVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjYNUDPxE1? NFfveWUzPCCq M4LKUXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MmHGNlEyPzB7OEi=
KAI-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGxJO69VQ>? NUTFU414OjRiaB?= MYjS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NXSwNYwyOjFzN{C5PFg>
SNK-6 NHW0WYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[xJO69VQ>? MXuyOEBp NW\1OoUxWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MlPzNlEyPzB7OEi=
KHYG-1 NUS3WZFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml61NUDPxE1? NWfCbVZWOjRiaB?= M1vlUXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NGrrOZMzOTF5MEm4PC=>
SNT-16 NX60e4VuSXCxcITvd4l{KEG|c3H5 M1rlfFEh|ryP MXq2JIg> MkXXTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MlLoNlEyPzB7OEi=
Jurkat NWTpTmU1SXCxcITvd4l{KEG|c3H5 MUSxJO69VQ>? MWq2JIg> NIH6bGFKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MnrINlEyPzB7OEi=
KAI-3 NYexT29OSXCxcITvd4l{KEG|c3H5 MnXUNUDPxE1? MVG2JIg> NWjQeWhWUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MnPINlEyPzB7OEi=
KHYG-1 NWHwNpdySXCxcITvd4l{KEG|c3H5 MoLnNUDPxE1? NWjScWVHPiCq NIezNW1KdmS3Y3XzJINmdGxiYYDvdJRwe2m| M{fmW|IyOTdyOUi4
SNT-13 MmTkRY51cX[rcnHsJGF{e2G7 M{\KVVEh|ryP NIDFUlAzPCCq MVvJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> MmrGNlEyPzB7OEi=
SNT-16 NHPSWmxCdnSrdnnyZYwhSXO|YYm= MX6xJO69VQ>? M2PzfVI1KGh? MlPUTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NGXl[nQzOTF5MEm4PC=>
KAI-3 M{nFcmFvfGm4aYLhcEBCe3OjeR?= MkS2NUDPxE1? MkjVNlQhcA>? MlHkTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX MlLyNlEyPzB7OEi=
SNK-6 M3rqdmFvfGm4aYLhcEBCe3OjeR?= MkLPNUDPxE1? NWPLbnVKOjRiaB?= M2X5N2lv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? MUiyNVE4ODl6OB?=
RAW 264.7 Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXPPFM5OTByIH7N NFPJeI81QCCq MYTS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NFzXUVgzOjR{N{G1OC=>
A375 M2rSbGFxd3C2b4Ppd{BCe3OjeR?= NV;nc2Q4OTBibl2= NGLVR48zPCCq Mo\aTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NFW1W3EzOzB5OUC4Ny=>
BLM Mki4RZBweHSxc3nzJGF{e2G7 NH3VSWMyOCCwTR?= Ml;0NlQhcA>? NEXTUVBKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NH63bmgzOzB5OUC4Ny=>
A375 Mo[yRZV1d3CqYXf5JGF{e2G7 M4WwNVExKG6P M4SxclEzKGh? NWj2eIROUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> MWKyN|A4QTB6Mx?=
BLM MVTBeZRweGijZ4mgRZN{[Xl? M1XLclExKG6P M1PifFEzKGh? NHXhXZFKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> M2G3c|I{ODd7MEiz
H1299 M4PZ[mFxd3C2b4Ppd{BCe3OjeR?= M3zkclgxKG6P M4C4W|I1KGh? NIjpUoFFVVOR MXjT[Y5{cXSrenXzJG5US0yFIHPlcIx{KHSxIF3TR{1l\XKrdnXkJIlEQS2rbnT1Z4VlKGGyb4D0c5Nqew>? MUWyOVMzOzZ7Mx?=
Hut-78 MUHGeY5kfGmxbjDBd5NigQ>? MWmxNFAhdk1? MVWyOEBp NHv6XWlFVVOR MULEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVExKGW6cILld5Nqd25? NYDLVIpXOjV4OEGzN|U>
H9 Mk\ESpVv[3Srb36gRZN{[Xl? NUTS[mZsOTByIH7N MWiyOEBp MXXEUXNQ MnOzSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOSCneIDy[ZN{cW:w M2XaOlI2PjhzM{O1
HH MoTTSpVv[3Srb36gRZN{[Xl? M3P4eFExOCCwTR?= NUG3No5rOjRiaB?= NYfvRpZoTE2VTx?= NX3xcWpZ\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u M3u5dlI2PjhzM{O1
Hut-78 NWTrU4t4VWmpcnH0bY9vKEG|c3H5 NV;VOmxlOTByIH7N NF\YeWczPCCq MXPEUXNQ M{LJWnJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MDW= NFfpOlgzPTZ6MUOzOS=>
HH M3nDZm1q\3KjdHnvckBCe3OjeR?= MkP2NVAxKG6P MUKyOEBp MUnEUXNQ M162UHJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MTW= NHTncGgzPTZ6MUOzOS=>
U937 Mn\LSpVv[3Srb36gRZN{[Xl? MYGxNFAhdk1? Mmr5OkBp Mne1TY5lfWOnczDJUE05KGW6cILld5Nqd25iaX6gUHBUNXO2aX31cIF1\WRiVUmzO{Bu[WO{b4DoZYdmew>? NVvEOnpVOjV5OUG0O|c>
human PBMC MXPGeY5kfGmxbjDBd5NigQ>? NWTjVW9COTByIH7N NGDXOlYzPCCq NVPVTXZ1UW6mdXPld{BKVC16IILlcIVie2V? NV;5RpUyOjV5OUG0O|c>
ES6 NF[4SmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMECyNUBvVQ>? MVTTRW5ITVJ?
SK-UT-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TTZWlEPTB;MD6xOlMhdk1? NWPhVmp{W0GQR1XS
SH-4 Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rtXWlEPTB;MD6xO|Mhdk1? MkDRV2FPT0WU
TE-9 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMUiyJI5O M2W1Z3NCVkeHUh?=
A253 NEnIR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3ySItpUUN3ME2wMlIxQCCwTR?= M4e4SXNCVkeHUh?=
no-10 NFzlR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjUT4xKSzVyPUCuNlEhdk1? MlzxV2FPT0WU
MMAC-SF NHjxeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXYWnhRUUN3ME2wMlIyPiCwTR?= M1fyVHNCVkeHUh?=
A101D M1nrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXwZZhuUUN3ME2wMlIzPSCwTR?= MV7TRW5ITVJ?
NTERA-S-cl-D1 NF7odXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMkSzJI5O NX;WZng2W0GQR1XS
8-MG-BA NGjWUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nuSWlEPTB;MD6yOUBvVQ>? MVjTRW5ITVJ?
KNS-42 M37sWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMkW4JI5O NYrtVmtjW0GQR1XS
LXF-289 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfWTWM2OD1yLkK2PUBvVQ>? NW\PdWRNW0GQR1XS
OVCAR-4 NGn0[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG2WHN3UUN3ME2wMlI5QSCwTR?= MnH1V2FPT0WU
LOUCY NILyOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfWS49KSzVyPUCuNlk{KG6P MWnTRW5ITVJ?
BB65-RCC NUL5R3JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Lv[GlEPTB;MD6zNFQhdk1? M3jJfHNCVkeHUh?=
D-542MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXtTWM2OD1yLkOyPUBvVQ>? NWjzPJEzW0GQR1XS
ONS-76 Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwM{Ogcm0> NFjzbHVUSU6JRWK=
BB30-HNC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL4TWM2OD1yLkOzOUBvVQ>? M3K5e3NCVkeHUh?=
KS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrVUVJKSzVyPUCuN|Qhdk1? NVLuXWptW0GQR1XS
A388 NGi2OYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHIeI5VUUN3ME2wMlM2PiCwTR?= NFfEd3pUSU6JRWK=
ES8 M3rFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;nemlEPTB;MD60JI5O NHLNXIZUSU6JRWK=
MZ2-MEL M2fWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fqS2lEPTB;MD60NFchdk1? Ml\rV2FPT0WU
HCC2998 MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nsdmlEPTB;MD60NVIhdk1? NVznSYd3W0GQR1XS
D-247MG M4DDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nnTmlEPTB;MD60NVMhdk1? Ml76V2FPT0WU
ACN M{HoT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPOcZdKSzVyPUCuOFE4KG6P MnXSV2FPT0WU
LB2518-MEL NGPFOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f5dmlEPTB;MD60NlUhdk1? NGDufXZUSU6JRWK=
ES1 NIG5U2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:2O2lEPTB;MD60N{BvVQ>? M1TjWHNCVkeHUh?=
HCE-T M3fMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvi[oV[UUN3ME2wMlQ{QSCwTR?= MYnTRW5ITVJ?
OS-RC-2 NWDV[W9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\tTWM2OD1yLkS0JI5O M3HuV3NCVkeHUh?=
MFH-ino M4e2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TsbmlEPTB;MD60OFMhdk1? MnPsV2FPT0WU
OCUB-M NH\zeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi3SWZVUUN3ME2wMlQ1PyCwTR?= NYj6e49wW0GQR1XS
CP66-MEL NFfxN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j6NGlEPTB;MD60O|Mhdk1? MnPOV2FPT0WU
LB771-HNC MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwNEe0JI5O MnzFV2FPT0WU
DSH1 NYT1XJdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK3TWM2OD1yLkS4JI5O M{S2ZXNCVkeHUh?=
HUTU-80 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnqelFIUUN3ME2wMlU{OyCwTR?= MWDTRW5ITVJ?
CESS M17nbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLjTWM2OD1yLkWzPEBvVQ>? NGnnWIZUSU6JRWK=
NCI-H747 NHfWS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljNTWM2OD1yLkWzPUBvVQ>? M4j4WXNCVkeHUh?=
HT-144 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwNUe2JI5O NF3zdpNUSU6JRWK=
COLO-829 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwNkG0JI5O NHixTo9USU6JRWK=
A4-Fuk MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLEUXkxUUN3ME2wMlYzOyCwTR?= NYX1PIJnW0GQR1XS
GI-ME-N M3vZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[zTWM2OD1yLk[zOEBvVQ>? NVLLbWJYW0GQR1XS
LB831-BLC NVPKbXBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTYTWM2OD1yLk[0NUBvVQ>? Mor1V2FPT0WU
HOP-62 M4PpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XLeGlEPTB;MD62OFchdk1? M3zrenNCVkeHUh?=
BB49-HNC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TBUGlEPTB;MD62OVIhdk1? MVvTRW5ITVJ?
D-336MG M1;Memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\nb|ZKSzVyPUCuOlU4KG6P MnvlV2FPT0WU
TK10 M16weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX0RmlXUUN3ME2wMlY4QSCwTR?= M2\EcnNCVkeHUh?=
Ramos-2G6-4C10 M3KzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHtc4tKSzVyPUCuOlk{KG6P NVTJNJJWW0GQR1XS
LB373-MEL-D M3;1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TJ[WlEPTB;MD63JI5O NIrM[2lUSU6JRWK=
SF126 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwN{CxJI5O MoHxV2FPT0WU
UACC-257 NGLibZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjKNnBKSzVyPUCuO|Ehdk1? M3T5dnNCVkeHUh?=
KINGS-1 NF\rUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3PUI5KSzVyPUCuO|IzKG6P M{jxbHNCVkeHUh?=
LS-513 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:5cmlEPTB;MD63N|khdk1? MXzTRW5ITVJ?
GI-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorJTWM2OD1yLke2OEBvVQ>? NUP5U41SW0GQR1XS
ES7 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13EXWlEPTB;MD63OlYhdk1? MW\TRW5ITVJ?
LB2241-RCC NGfXfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT1TWM2OD1yLkiwOEBvVQ>? NXPlR5ZwW0GQR1XS
D-263MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfJSm5[UUN3ME2wMlgxPyCwTR?= NF3hUYFUSU6JRWK=
SW684 NVrRT5ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwOEKxJI5O NWey[21YW0GQR1XS
ML-2 Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfIbZpKSzVyPUCuPFIyKG6P Ml7qV2FPT0WU
SK-LMS-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITNNlJKSzVyPUCuPFU1KG6P Mo\qV2FPT0WU
TE-5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr3TWM2OD1yLki2OUBvVQ>? M2WzPXNCVkeHUh?=
QIMR-WIL NEHFe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{n0cWlEPTB;MD64PFkhdk1? MXvTRW5ITVJ?
NCI-H1355 MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPM[45zUUN3ME2wMlg6PSCwTR?= M1XEfnNCVkeHUh?=
SNB75 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXHTWM2OD1yLkmxNkBvVQ>? NF7TUnFUSU6JRWK=
RXF393 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXVTWM2OD1yLkmxOEBvVQ>? MnzIV2FPT0WU
IST-MEL1 NFjrUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPxPWJJUUN3ME2wMlkyPyCwTR?= M2C0RXNCVkeHUh?=
SF268 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwOUKzJI5O MX;TRW5ITVJ?
KALS-1 MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfoTWM2OD1yLkmyOUBvVQ>? NUnPOWxpW0GQR1XS
HC-1 NFfDPGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwOUe1JI5O NIHobWZUSU6JRWK=
SW872 NFThXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH4TWM2OD1yLkm5OkBvVQ>? NWX4[5REW0GQR1XS
PSN1 M1LDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\oTWM2OD1zLkCxJI5O NWHxWJBwW0GQR1XS
TE-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHL2VXRKSzVyPUGuNFMhdk1? M2TyWXNCVkeHUh?=
TE-10 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTFwMEOgcm0> MVTTRW5ITVJ?
RKO Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX6TWM2OD1zLkC2JI5O MYXTRW5ITVJ?
LC-2-ad MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf3enRTUUN3ME2xMlA5KG6P Mnr6V2FPT0WU
SK-MM-2 NGS0VoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\QTWM2OD1zLkC5JI5O M1X4PXNCVkeHUh?=
VA-ES-BJ M{jj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XPS2lEPTB;MT6wPUBvVQ>? NYXuNoFEW0GQR1XS
MZ7-mel MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn3U|lKSzVyPUGuNFkhdk1? M3TaTXNCVkeHUh?=
D-392MG NX\TNogzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojDTWM2OD1zLkGgcm0> MojVV2FPT0WU
CCRF-CEM NUT1PZdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFwMUOgcm0> M3vmfHNCVkeHUh?=
EM-2 NYP0b5JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u5cWlEPTB;MT6xOkBvVQ>? M4PRRXNCVkeHUh?=
HAL-01 M1;GOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwMUigcm0> NIT5OlVUSU6JRWK=
TE-8 NIH0SWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFwMUmgcm0> NHu0enlUSU6JRWK=
NCI-H1882 NYTvRW5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH32cGpKSzVyPUGuNkBvVQ>? M3;PSHNCVkeHUh?=
Daudi M3jtN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFwMkKgcm0> MXnTRW5ITVJ?
BL-41 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjD[I5IUUN3ME2xMlI2KG6P NHXKeW9USU6JRWK=
SR NIfLcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILreWFKSzVyPUGuNlUhdk1? NVzkfY5jW0GQR1XS
KM12 NUDNbWlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwMkegcm0> M1PLOnNCVkeHUh?=
K5 MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X1[mlEPTB;MT6yPEBvVQ>? M4q4b3NCVkeHUh?=
A3-KAW MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXWdWpKSzVyPUGuNlghdk1? M4i1Z3NCVkeHUh?=
CMK MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHVWVlKSzVyPUGuNlkhdk1? MkjiV2FPT0WU
Calu-6 MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS1TWM2OD1zLkK5JI5O M3naPXNCVkeHUh?=
IST-SL2 NVvz[3ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPuTmtKUUN3ME2xMlMyKG6P MVHTRW5ITVJ?
OPM-2 NWLselNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLuTWM2OD1zLkOzJI5O MXfTRW5ITVJ?
DU-4475 M{i0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwM{[gcm0> NUfzeotHW0GQR1XS
ECC12 NVjWRmw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz1TWM2OD1zLkO3JI5O M2nZZXNCVkeHUh?=
L-540 NFXwOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFwM{egcm0> MU\TRW5ITVJ?
CAS-1 MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvvd3FJUUN3ME2xMlM4KG6P MoTRV2FPT0WU
PF-382 NYr0bm5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHpUVZKUUN3ME2xMlQ4KG6P MlO3V2FPT0WU
LS-411N MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfPXoYxUUN3ME2xMlU{KG6P M37zT3NCVkeHUh?=
NCI-H69 Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwNUSgcm0> NEXXV4JUSU6JRWK=
NB12 NGnuZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe4PZBKSzVyPUGuOVYhdk1? M4WxcHNCVkeHUh?=
HEL MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrpcZdKSzVyPUGuOlEhdk1? NEPaSnBUSU6JRWK=
GCIY Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvSRVJ5UUN3ME2xMlYzKG6P M2fMVnNCVkeHUh?=
EHEB NH;CUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj1XmdKSzVyPUGuOlchdk1? NXHXTpQ1W0GQR1XS
TGBC1TKB MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFwN{Ggcm0> Ml:zV2FPT0WU
KURAMOCHI MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnq2TWM2OD1zLkeyJI5O MoPwV2FPT0WU
U-266 MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFwN{[gcm0> MXHTRW5ITVJ?
LC4-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfaU5hFUUN3ME2xMlc6KG6P NWq1cIRbW0GQR1XS
NCI-H2126 NWnDbZB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVOxWI9jUUN3ME2xMlghdk1? MXHTRW5ITVJ?
NCI-H1092 M{freGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGxWIVKSzVyPUGuPEBvVQ>? MYrTRW5ITVJ?
GB-1 NITleHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFwOEGgcm0> MkHOV2FPT0WU
MV-4-11 M1TYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwOEKgcm0> NXjZ[VdXW0GQR1XS
Becker M1TwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PRVGlEPTB;MT64N{BvVQ>? NVu4W|hJW0GQR1XS
MPP-89 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vlOmlEPTB;MT64PUBvVQ>? M2frXHNCVkeHUh?=
BE-13 M3LPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\pTWM2OD1zLkmzJI5O MknSV2FPT0WU
697 NUH6fFZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rDcmlEPTB;MT65PUBvVQ>? NHrLc5ZUSU6JRWK=
NKM-1 NX6wdpFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJibl2= NVPneok2W0GQR1XS
NB13 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELT[mJKSzVyPUKgcm0> NGW0UlZUSU6JRWK=
LS-123 Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFKxXmtKSzVyPUKuNFIhdk1? MonHV2FPT0WU
NB17 NF22W3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r6VmlEPTB;Mj6wOEBvVQ>? MVvTRW5ITVJ?
LAN-6 M{\PNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HWcWlEPTB;Mj6wOUBvVQ>? NGjKPZZUSU6JRWK=
EW-24 NYPNbFBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPNOYp2UUN3ME2yMlA5KG6P M4q0dXNCVkeHUh?=
NOS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;OWmlEPTB;Mj6xNUBvVQ>? NF;wOpZUSU6JRWK=
BL-70 NGe4T4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fQWGlEPTB;Mj6xNkBvVQ>? NIDMOGRUSU6JRWK=
GT3TKB M2LZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fuPGlEPTB;Mj6xNkBvVQ>? NFLPN2RUSU6JRWK=
HH M1LrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7PTWM2OD1{LkGzJI5O MVzTRW5ITVJ?
KE-37 M3v0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXveVVKSzVyPUKuNVMhdk1? M2DzWHNCVkeHUh?=
MOLT-4 Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJwMUOgcm0> MYTTRW5ITVJ?
EKVX NEDXVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjRPFBKSzVyPUKuNVQhdk1? NIDLVY9USU6JRWK=
KGN NXfq[FRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfmV|ZKSzVyPUKuNVUhdk1? NY\CVWpIW0GQR1XS
ES4 NFTEVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M134Z2lEPTB;Mj6xOkBvVQ>? M3\BdXNCVkeHUh?=
SJSA-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwMkGgcm0> NWr2d2pFW0GQR1XS
KMOE-2 NID2PXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm0TWM2OD1{LkKzJI5O NUn6[pU{W0GQR1XS
NB5 NWHGU5VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHNTWM2OD1{LkK3JI5O MYXTRW5ITVJ?
BC-1 NX3lUJZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\ifnBKSzVyPUKuN|Ehdk1? NXq4OW1JW0GQR1XS
NB10 NET3enhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDieWJKSzVyPUKuN|Ihdk1? NUH1V2d5W0GQR1XS
RPMI-8226 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXwTWM2OD1{LkO1JI5O Mm\tV2FPT0WU
SCC-3 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H3bmlEPTB;Mj6zO{BvVQ>? MUPTRW5ITVJ?
ARH-77 Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJwM{igcm0> MUPTRW5ITVJ?
NCI-H748 NH\r[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnLTWM2OD1{LkO5JI5O M{nYfHNCVkeHUh?=
KU812 M3\3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnNd4dKSzVyPUKuOFIhdk1? M3O1RnNCVkeHUh?=
NCI-H64 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;NNpNHUUN3ME2yMlQ1KG6P MoTnV2FPT0WU
NB69 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTNRmxKSzVyPUKuOFYhdk1? M{HxbHNCVkeHUh?=
KNS-81-FD NXTV[lJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnKSZpKSzVyPUKuOFghdk1? MYjTRW5ITVJ?
LB1047-RCC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILke4JKSzVyPUKuOVchdk1? MlrGV2FPT0WU
EB-3 NHLmSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z6W2lEPTB;Mj62OkBvVQ>? NHizWGZUSU6JRWK=
Mo-T MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[yNIJKSzVyPUKuO|Qhdk1? MWTTRW5ITVJ?
EW-16 M4[wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoCzTWM2OD1{Lke1JI5O Mk[1V2FPT0WU
CTV-1 NHviXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrzToZKSzVyPUKuPEBvVQ>? MVzTRW5ITVJ?
ETK-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjzTWM2OD1{Lki0JI5O Mlz2V2FPT0WU
C2BBe1 M4Do[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPTXZJKSzVyPUKuPFkhdk1? M{XTfXNCVkeHUh?=
MOLT-16 NGLYNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjMPJd1UUN3ME2yMlg6KG6P MmTsV2FPT0WU
SW954 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJwOTDuUS=> NWTMVXJ[W0GQR1XS
HT NH\IcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;Y[mV1UUN3ME2zMlAzKG6P NXLndoZoW0GQR1XS
KARPAS-299 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDDVWFKSzVyPUOuNFYhdk1? M3K1RXNCVkeHUh?=
MONO-MAC-6 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHUVplLUUN3ME2zMlEhdk1? NFGyT3ZUSU6JRWK=
CGTH-W-1 NHnxXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;yZmlEPTB;Mz6xJI5O M4[zWnNCVkeHUh?=
SK-PN-DW NFjxbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTNwMUSgcm0> NX7UcXdCW0GQR1XS
CW-2 NXiwVFF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknNTWM2OD1|LkKxJI5O MUnTRW5ITVJ?
SK-N-DZ MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XD[2lEPTB;Mz6yOkBvVQ>? MYHTRW5ITVJ?
NEC8 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rGdWlEPTB;Mz6zOUBvVQ>? M4XtWHNCVkeHUh?=
LB996-RCC M1T2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PsXGlEPTB;Mz60JI5O MmLEV2FPT0WU
DB Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nQcWlEPTB;Mz60NUBvVQ>? MYjTRW5ITVJ?
TE-15 MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PPUGlEPTB;Mz60N{BvVQ>? M1HJOXNCVkeHUh?=
COR-L88 NX\6dXFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzqfXZKSzVyPUOuOFchdk1? M2nF[3NCVkeHUh?=
LAMA-84 NX;0RYhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[3WmlEPTB;Mz60PUBvVQ>? NFfRZnRUSU6JRWK=
MEG-01 M3HEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K5RWlEPTB;Mz60PUBvVQ>? MmKzV2FPT0WU
LOXIMVI M1HDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHUSZdKUUN3ME2zMlUhdk1? M3vkSXNCVkeHUh?=
RPMI-8402 NGXpRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnwcldKSzVyPUOuOUBvVQ>? Mo[1V2FPT0WU
KARPAS-45 NEjvcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TDd2lEPTB;Mz61OEBvVQ>? MnfEV2FPT0WU
HCC1187 NX35RW92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTNwNUSgcm0> MWHTRW5ITVJ?
MZ1-PC M1PmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\tN2lEPTB;Mz61OEBvVQ>? M{DQRnNCVkeHUh?=
no-11 MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTNwNUWgcm0> NEX1[25USU6JRWK=
EVSA-T MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTNwNjDuUS=> MYrTRW5ITVJ?
DJM-1 M4PqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvLTWM2OD1|Lk[zJI5O MXjTRW5ITVJ?
COLO-684 MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK5TWM2OD1|Lk[2JI5O NV7hPFVOW0GQR1XS
NMC-G1 NHW0VZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTNwNkigcm0> NF7jelhUSU6JRWK=
LC-1F MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTNwN{Sgcm0> MlGwV2FPT0WU
RL95-2 NFXzdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTNwN{mgcm0> NX7BdYIxW0GQR1XS
COLO-320-HSR MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3KVGlKSzVyPUOuPVIhdk1? Mmn4V2FPT0WU
RCC10RGB NH3XdlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\yXVRKSzVyPUOuPVMhdk1? MWnTRW5ITVJ?
HD-MY-Z MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e2SWlEPTB;Mz65N{BvVQ>? MnzmV2FPT0WU
NCI-H2141 NFHGU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX4SZB4UUN3ME20MlA2KG6P NF\zT2hUSU6JRWK=
K-562 NIDuSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Ow[mlEPTB;ND6xNkBvVQ>? NHX3SXVUSU6JRWK=
NCI-H1648 NYrpOoZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFyxVWxKSzVyPUSuNVMhdk1? M2i3SnNCVkeHUh?=
OMC-1 NIO4VXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT0eW1KSzVyPUSuNVghdk1? MVjTRW5ITVJ?
LB647-SCLC M1HCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTRwMkKgcm0> MmHUV2FPT0WU
TE-12 M4rwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjtNZRsUUN3ME20MlI2KG6P NWq2SnhjW0GQR1XS
NOMO-1 NW\2OZY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7BPJVKSzVyPUSuN|Mhdk1? M1TSR3NCVkeHUh?=
Raji MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYexTFFmUUN3ME20MlQ3KG6P M3y4NHNCVkeHUh?=
NALM-6 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlKzTWM2OD12LkS5JI5O MYTTRW5ITVJ?
HL-60 MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFv1WWJKSzVyPUSuOlchdk1? NFHKb2VUSU6JRWK=
IST-SL1 NHr6T21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DiZmlEPTB;ND62PEBvVQ>? NEiwbFRUSU6JRWK=
MHH-PREB-1 NUDCXFNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH4TVZNUUN3ME20Mlg3KG6P NGfMV|BUSU6JRWK=
MHH-NB-11 Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELXXWVKSzVyPUSuPVEhdk1? NGXEfYpUSU6JRWK=
JiyoyeP-2003 NWXKT3ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmruTWM2OD13IH7N M2\lZnNCVkeHUh?=
SBC-1 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTVwMEGgcm0> NFP5NlFUSU6JRWK=
CHP-126 NWPEO5FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDybpR5UUN3ME21MlA3KG6P NULVSnFEW0GQR1XS
LU-139 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHlb2lnUUN3ME21MlE{KG6P M4[zd3NCVkeHUh?=
NCI-SNU-5 M332UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3CTWM2OD13LkG3JI5O NHfKZlRUSU6JRWK=
SW962 NV2weYFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fwRmlEPTB;NT6yNUBvVQ>? NHzNXIJUSU6JRWK=
EW-1 NIjDRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L0fmlEPTB;NT6zNUBvVQ>? MoS3V2FPT0WU
NCI-H1417 M4i0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTVwNUGgcm0> NUjyOI9{W0GQR1XS
LU-65 NXLiWJVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjVb3oxUUN3ME21Mlg1KG6P NVzQR2F{W0GQR1XS
D-502MG MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[2XZVKSzVyPU[uN|chdk1? NHW0ZWJUSU6JRWK=
BC-3 NEnOXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXqwbI06UUN3ME22MlYyKG6P M4fZfXNCVkeHUh?=
GDM-1 M{\5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXMZVJ1UUN3ME22Mlc4KG6P NVjPOmZPW0GQR1XS
NCI-H2196 NYrXOlFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nEUWlEPTB;Nj64JI5O NEDqW2xUSU6JRWK=
NB1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7YZohKSzVyPU[uPFghdk1? MVnTRW5ITVJ?
NCI-H345 NYD3RoJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvaTWJKSzVyPUeuNkBvVQ>? MnzBV2FPT0WU
SU-DHL-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:2TWM2OD15LkK0JI5O Mn\oV2FPT0WU
JVM-2 MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[5fVRQUUN3ME23MlI5KG6P MVHTRW5ITVJ?
LU-134-A MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n3fmlEPTB;Nz6zPUBvVQ>? MVjTRW5ITVJ?
NCI-H1694 NEDMeFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TyPWlEPTB;Nz61PEBvVQ>? Ml;UV2FPT0WU
NCI-SNU-16 MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTdwNkWgcm0> NVvoXJlWW0GQR1XS
L-363 M37kTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fiO2lEPTB;Nz63JI5O MUHTRW5ITVJ?
KG-1 NXy5bVdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTdwOUSgcm0> NF24Ro9USU6JRWK=
MN-60 NFzBWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfKOWRKSzVyPUiuNVQhdk1? Ml\jV2FPT0WU
NB6 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T4UGlEPTB;OD60PEBvVQ>? MoDxV2FPT0WU
MLMA NEfMO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PkfWlEPTB;OD64OUBvVQ>? NV\5[JdDW0GQR1XS
ATN-1 NHj6U5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\vXGlEPTB;OD64PUBvVQ>? MX;TRW5ITVJ?
SK-NEP-1 NXvT[nB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP6TWM2OD17LkCxJI5O Mm\wV2FPT0WU
DMS-114 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fQRmlEPTB;OT62NkBvVQ>? NUTNNJpXW0GQR1XS
CTB-1 NHXuUGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTlwNkegcm0> Mn3OV2FPT0WU
NCI-H2081 NFraXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvic5F1UUN3ME2xNE4xQSCwTR?= M2q3bXNCVkeHUh?=
ES5 M36xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nwfGlEPTB;MUCuN|ghdk1? MWnTRW5ITVJ?
HCC1599 MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTsTWM2OD1zMT65NUBvVQ>? NUXqUlluW0GQR1XS
NCI-H23 MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7aZ|NoUUN3ME2xNk4yOiCwTR?= NXjHZ2lHW0GQR1XS
NCI-H1581 Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\pTWlEPTB;MUKuNlghdk1? MYXTRW5ITVJ?
JVM-3 M4jtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITFTXBKSzVyPUGyMlk6KG6P NUGwVHlRW0GQR1XS
NCI-SNU-1 NYjldJlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7LUmtKSzVyPUGzMlE6KG6P MY\TRW5ITVJ?
NB7 MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m0[2lEPTB;MUWuPVIhdk1? M2qzZXNCVkeHUh?=
JAR M4C4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXSNGtKSzVyPUG2MlE{KG6P MVHTRW5ITVJ?
TGW MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkixTWM2OD1zNj60PEBvVQ>? Ml2wV2FPT0WU
U-87-MG NIjRPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF4Lke2JI5O NYD3T4hxW0GQR1XS
NCI-H1436 M33tXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrITWM2OD1zNz6wNUBvVQ>? NWL1eJNQW0GQR1XS
GOTO M1PyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfJO4NKSzVyPUG3MlA3KG6P M3iyXXNCVkeHUh?=
COLO-800 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHMelU5UUN3ME2xO{43PCCwTR?= NHnNPIxUSU6JRWK=
MFM-223 M1zVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfzTWM2OD1zNz65NUBvVQ>? M4HqPXNCVkeHUh?=
EW-18 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC3WIpOUUN3ME2xO{46PiCwTR?= MknNV2FPT0WU
NB14 MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjU[2xvUUN3ME2xO{46QCCwTR?= MkfWV2FPT0WU
EB2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL1T2FKSzVyPUG4MlA5KG6P NVfaO2ZoW0GQR1XS
EoL-1- MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF6LkOxJI5O NWq3VpQ4W0GQR1XS
NCCIT NXPydGVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\VTWM2OD1zOD6zOkBvVQ>? M3Xw[nNCVkeHUh?=
DG-75 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTvOXhVUUN3ME2xPE43OSCwTR?= NVHWdJVxW0GQR1XS
HCC2218 M3vs[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXkSoJKSzVyPUG5MlUhdk1? NGfyeZVUSU6JRWK=
TE-6 Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW2TWM2OD1{MD6wPEBvVQ>? MnHuV2FPT0WU
SF539 NWPhPXk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPRS3JKSzVyPUKwMlY4KG6P NITz[WNUSU6JRWK=
NCI-H446 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJzLkG4JI5O MUHTRW5ITVJ?
IST-MES1 M1\2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\lNm1TUUN3ME2yNk44PyCwTR?= MnrlV2FPT0WU
NCI-H82 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJ|LkCyJI5O MknnV2FPT0WU
HCC2157 NVvOb3FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H0WGlEPTB;MkOuNVMhdk1? NVOzRpFnW0GQR1XS
EW-12 MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S5SWlEPTB;MkOuNVchdk1? NWD3W4k4W0GQR1XS
SIMA NVK4TIh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[xTmlEPTB;MkOuN|ghdk1? M1PXSnNCVkeHUh?=
DOHH-2 MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfG[HJKSzVyPUKzMlQ2KG6P Mn\UV2FPT0WU
IM-9 NWD0cmpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ToOmlEPTB;MkOuOVQhdk1? MlHFV2FPT0WU
EC-GI-10 NEnkVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\3Z2lEPTB;MkSuNlMhdk1? M{nJbHNCVkeHUh?=
HDLM-2 M3v6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUmw[2ttUUN3ME2yOE42PCCwTR?= NH7iV2dUSU6JRWK=
LS-1034 M3njXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXafGhKSzVyPUK1Mlc2KG6P MkDJV2FPT0WU
REH NEXpdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj5fJVOUUN3ME2yOk41OSCwTR?= M1rPbXNCVkeHUh?=
LU-165 NV3KOZZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzGWVFKSzVyPUK2MlczKG6P M3r2OXNCVkeHUh?=
NH-12 NVXndGFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJ5Lk[3JI5O M4HrZXNCVkeHUh?=
WSU-NHL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XvOWlEPTB;MkiuN|khdk1? NHnZNpBUSU6JRWK=
ECC4 NXT1OXUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn2OmxFUUN3ME2yPE44QSCwTR?= MlzaV2FPT0WU
OCI-AML2 M2n0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jmRmlEPTB;MkmuOlkhdk1? NUfwVmZjW0GQR1XS
EW-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;RfIFKSzVyPUOwMlU6KG6P MlXtV2FPT0WU
NCI-H526 M2Dk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzPWFNXUUN3ME2zNk42PCCwTR?= NUDXbXl5W0GQR1XS
NCI-H719 M3PuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTN2LkOxJI5O MUHTRW5ITVJ?
KARPAS-422 Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTN3LkC0JI5O MYrTRW5ITVJ?
SK-MEL-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTN3LkG3JI5O NEPhZ4NUSU6JRWK=
ES3 NIfxUJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTN3LkG5JI5O MWDTRW5ITVJ?
UACC-812 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\5cGlEPTB;M{WuOFQhdk1? NGTmPXpUSU6JRWK=
C8166 NHrVe5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\VTWM2OD1|NT63JI5O NXPudG4{W0GQR1XS
MDA-MB-134-VI MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTjZWxKSzVyPUO1Mlg4KG6P NWjWTJFSW0GQR1XS
D-283MED NEm5WXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq0TottUUN3ME2zO{44QSCwTR?= NUD5d4VwW0GQR1XS
SHP-77 MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTTTWM2OD1|OD6wN{BvVQ>? MXPTRW5ITVJ?
NCI-H2227 M4HSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTRyLkS5JI5O MXTTRW5ITVJ?
SKM-1 NFe3bFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTR{Lk[zJI5O NXjzSnVLW0GQR1XS
L-428 M3[yfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYG3fpB[UUN3ME20N{45PiCwTR?= NXvmSFZHW0GQR1XS
RPMI-6666 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTR3Lki5JI5O NFHGNZNUSU6JRWK=
NCI-H716 M{TQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTR6LkixJI5O Mm\TV2FPT0WU
DMS-79 M4rndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G1d2lEPTB;NUCuO|Ehdk1? M2rKWHNCVkeHUh?=
RS4-11 NXno[GM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrveodKSzVyPUWwMlg5KG6P MYfTRW5ITVJ?
NCI-H720 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTVzLkGxJI5O NES5bXhUSU6JRWK=
MC-CAR NFPNc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4S3OmlEPTB;NUGuOVIhdk1? M1S3OHNCVkeHUh?=
TALL-1 MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDxV5VJUUN3ME21N{46OSCwTR?= M2HCSHNCVkeHUh?=
NCI-N87 NFWzd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[wTWM2OD13ND6xPEBvVQ>? MXPTRW5ITVJ?
P30-OHK MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmf6TWM2OD13ND62NUBvVQ>? NHj5ZYZUSU6JRWK=
LP-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fhRWlEPTB;NkGuNlghdk1? NYD3RZJDW0GQR1XS
YT MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M123cWlEPTB;NkGuPEBvVQ>? NH;oSmNUSU6JRWK=
MRK-nu-1 NEfJfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\aTWM2OD14MT64NkBvVQ>? NYruXXlqW0GQR1XS
BT-474 NULHOIdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTZ3IH7N MX\TRW5ITVJ?
NCI-H322M NIHvOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFeybmxKSzVyPU[2MlEyKG6P NELsPJdUSU6JRWK=
NCI-H128 M4i2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTd2Lke3JI5O Mki5V2FPT0WU
KMS-12-PE Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzxTWM2OD15Nj6yOEBvVQ>? NF\DSmNUSU6JRWK=
KP-N-YS NHvDc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;FU2lEPTB;N{[uO|Qhdk1? NUXRSXM5W0GQR1XS
ALL-PO MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrzNWRKSzVyPUe3MlY3KG6P M4LUV3NCVkeHUh?=
EW-13 M2Pscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnmPZBlUUN3ME23O{44PiCwTR?= NFX0T5FUSU6JRWK=
EW-11 NHTZbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTd6LkWyJI5O NGP0Zm9USU6JRWK=
SK-N-FI MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICyd3ZKSzVyPUiwMlIhdk1? M3n2ZnNCVkeHUh?=
CAL-148 M2nsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTlSW1KSzVyPUixMlg1KG6P M17P[nNCVkeHUh?=
RL M1T6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXtSGJKSzVyPUi2MlA6KG6P NWexZ5FYW0GQR1XS
AM-38 MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTh6LkC4JI5O NFr1c4RUSU6JRWK=
RH-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fKWWlEPTB;OUmuPFUhdk1? NIPpdoFUSU6JRWK=
NCI-H1770 NYXmPIE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFyMj60PUBvVQ>? NFLQbXFUSU6JRWK=
SIG-M5 M13vNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFyNT6wOkBvVQ>? MoCzV2FPT0WU
GR-ST NGruRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULFOlE4UUN3ME2xNVMvOzRibl2= NVyweHRxW0GQR1XS
ST486 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFzND6wOkBvVQ>? Mn\JV2FPT0WU
NCI-H1650 NVm0PYFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFzNT6yPUBvVQ>? NUL6PWRoW0GQR1XS
MHH-CALL-2 MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jBNmlEPTB;MUG1Mlchdk1? MmLSV2FPT0WU
BV-173 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\STWM2OD1zMkKuO|Ehdk1? Mo\EV2FPT0WU
MC116 NFnOXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF2OD64OUBvVQ>? NFHsTIpUSU6JRWK=
NCI-H524 NHvwXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfEb|JKSzVyPUG1PU4yKG6P NIPUUIhUSU6JRWK=
SCLC-21H NVO1e5R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXpdWtKSzVyPUG1PU41OSCwTR?= M3;FZnNCVkeHUh?=
NCI-H1304 MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn4cnVYUUN3ME2xOlkvOjFibl2= MUfTRW5ITVJ?
NCI-H510A MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG2OIt[UUN3ME2xPFUvOzdibl2= NUDtT41vW0GQR1XS
NCI-H209 M13lcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF7Nj61NkBvVQ>? Mn75V2FPT0WU
KM-H2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\SRotGUUN3ME2xPVcvODVibl2= MX\TRW5ITVJ?
NCI-H1395 MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJzMD6xN{BvVQ>? NF7EZlRUSU6JRWK=
NCI-H1155 M2nqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrYVXpmUUN3ME2yN|AvOzJibl2= M4q1WXNCVkeHUh?=
COR-L279 NYPO[|dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPuTWM2OD1{NUKuNVchdk1? NICwcVZUSU6JRWK=
NCI-H1299 NHPVfJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJ4MT63NUBvVQ>? M1TQ[nNCVkeHUh?=
EW-22 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;EXYFxUUN3ME2yOlMvPzVibl2= M{PwNnNCVkeHUh?=
SK-MEL-2 NXTvV|hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr3UlVKSzVyPUK4NU46KG6P NV3iSoRqW0GQR1XS
KASUMI-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ6Mz6wOUBvVQ>? MlPFV2FPT0WU
NCI-H187 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLFTWM2OD1{OEeuNFghdk1? M2PVeHNCVkeHUh?=
NCI-H2171 MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJ6OD65NkBvVQ>? MmWwV2FPT0WU
LNCaP-Clone-FGC M3nEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHtTWM2OD1{OUWuNlYhdk1? NF7zWJVUSU6JRWK=
NCI-H1522 NIHoU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXvSppKSzVyPUOwO{4xPSCwTR?= M17rfnNCVkeHUh?=
SCH NF7sRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVqxeJJTUUN3ME2zNlIvOjJibl2= NEnRSG5USU6JRWK=
THP-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPRTWM2OD1|MkKuOkBvVQ>? MnfGV2FPT0WU
SNU-C1 NIXpS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\Jb3FKSzVyPUO2Nk4xQSCwTR?= MXfTRW5ITVJ?
CA46 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3flOmlEPTB;M{ezMlY{KG6P MV3TRW5ITVJ?
NCI-H1963 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX5NXZlUUN3ME2zPFYvOTlibl2= NV36bVBOW0GQR1XS
DEL NXTseY1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVntdFd1UUN3ME2zPVEvOjdibl2= MV;TRW5ITVJ?
TUR MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETiZodKSzVyPUO5Ok43OSCwTR?= Mnu2V2FPT0WU
NCI-H226 NU\JVGFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2K1RmlEPTB;NECzMlI{KG6P NGXOTINUSU6JRWK=
COLO-668 NGHNXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHO[IhKSzVyPUSwN{42PyCwTR?= MV;TRW5ITVJ?
CPC-N MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3sTWM2OD12MEOuO|chdk1? M1nufHNCVkeHUh?=
NCI-H889 M{\vfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTR4MT65NkBvVQ>? NV[4ZVR1W0GQR1XS
J-RT3-T3-5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHLTWM2OD13M{KuOVchdk1? M3ryN3NCVkeHUh?=
MSTO-211H MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nFNWlEPTB;NUe0MlI3KG6P NGPKcmlUSU6JRWK=
SCC-15 NEfHS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TvOGlEPTB;Nk[3MlQ4KG6P M4nJNXNCVkeHUh?=
SUP-T1 M{jMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfMTWM2OD14OE[uNFQhdk1? M120[XNCVkeHUh?=
DMS-153 NUDFSY9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r0TGlEPTB;N{S2Mlg{KG6P Ml7NV2FPT0WU
MS-1 M4G3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV63eI5{UUN3ME23OVkvPDJibl2= NFTacYpUSU6JRWK=
TC-YIK M4f6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DWb2lEPTB;N{ixMlAyKG6P NYj4cZQxW0GQR1XS
RPMI-8866 NYO2XJlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HCeGlEPTB;MUCwOk4zQCEQvF2= M2PmZnNCVkeHUh?=
KY821 NH;m[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe5NnpKSzVyPUGwN|YvODRizszN NXLQR5k2W0GQR1XS
P31-FUJ MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFzMUKuO|Uh|ryP NWDNSGxDW0GQR1XS
COLO-824 MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqyTWM2OD1zMk[xMlc5KM7:TR?= M1nxPXNCVkeHUh?=
U-698-M MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3HTWM2OD1{Mk[yMlE2KM7:TR?= Ml3vV2FPT0WU
TE-441-T NW\IS2VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXvTWM2OD1{NUKxMlch|ryP MXnTRW5ITVJ?
IMR-5 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTN2MEmuOlIh|ryP NGjUdlFUSU6JRWK=
NCI-H1838 MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m4d2lEPTB;NEG4Ok4{OiEQvF2= MVvTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo 2% DMSO+30% PEG 300+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID